Johnson & Johnson (NYSE:JNJ) Shares Purchased by Silver Oak Securities Incorporated

Silver Oak Securities Incorporated boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 14.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,592 shares of the company’s stock after buying an additional 976 shares during the period. Silver Oak Securities Incorporated’s holdings in Johnson & Johnson were worth $1,088,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Vinva Investment Management Ltd grew its position in Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock worth $17,988,000 after acquiring an additional 7,110 shares during the period. Financial Counselors Inc. grew its holdings in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock worth $29,996,000 after purchasing an additional 9,309 shares during the period. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $949,000. Meridian Investment Counsel Inc. raised its holdings in Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after buying an additional 3,710 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after buying an additional 102,502 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Finally, Stifel Nicolaus reduced their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $153.10 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a market capitalization of $368.61 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The business’s fifty day moving average price is $147.42 and its 200 day moving average price is $156.08.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the firm posted $2.29 EPS. The company’s revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.